Indivior Pharmaceuticals
Indivior plc is a British specialty pharmaceutical company dedicated to developing innovative medicines to treat substance use disorders and opioid addiction. The company researches, manufactures, and distributes pharmaceutical products, prominently featuring Suboxone (buprenorphine and naloxone) and Sublocade (buprenorphine extended-release) for treating opioid use disorder, alongside treatments for alcohol use disorder and overdose rescue. Its core operations encompass pharmaceutical research, clinical trial management, regulatory compliance, and global commercial distribution. Revenue is derived primarily from the commercial sales of its addiction treatment drugs to healthcare providers, hospitals, and government agencies worldwide. Indivior holds a leading global market position in addiction treatment pharmaceuticals. The company is headquartered in Richmond, Virginia, United States, with legal domicile in Dublin, Ireland, and its ordinary shares trade on the London Stock Exchange and the Nasdaq Global Select Market.
5 of the funds FundTelligence covers report a position in Indivior Pharmaceuticals.
- Legal name
- Indivior Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United Kingdom
- Funds holding it
- 5
- Exposure themes
- Addiction, Mental Health, Psychiatry
Funds holding Indivior Pharmaceuticals
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.06 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.35 % (full portfolio disclosed, October 2026)
- JPM Global Value Fund — JPM · 0.2 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.05 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)